A randomised phase 2a study to investigate the effects of blocking interleukin-33 with tozorakimab in patients hospitalised with COVID-19: ACCORD-2.
Wilkinson T, De Soyza A, Carroll M, Chalmers JD, Crooks MG, Griffiths G, Shankar-Hari M, Ho LP, Horsley A, Kell C, Lara B, Mishra B, Moate R, Page C, Pandya H, Raw J, Reid F, Saralaya D, Scott IC, Siddiqui S, Ustianowski A, van Zuydam N, Woodcock A, Singh D.
Wilkinson T, et al. Among authors: crooks mg.
ERJ Open Res. 2023 Oct 2;9(5):00249-2023. doi: 10.1183/23120541.00249-2023. eCollection 2023 Sep.
ERJ Open Res. 2023.
PMID: 37868151
Free PMC article.